GE Healthcare announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility. Optison is a contrast agent that may improve the visualization of the left ventricular border — an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. Upon approval, GE Healthcare will provide supply of Optison to the U.S. market from its manufacturing facility in Oslo, becoming the only contrast media manufacturer to supply its own stock for the United States.

Agfa HealthCare previewed version 2 of its Impax Business Intelligence solution to the U.S. market at the 98th annual meeting of the Radiological Society of North America in November 2012.

At the 98th annual meeting of the Radiological Society of North America (RSNA) in November 2012, Siemens Healthcare demonstrated continued commitment to its Agenda 2013 global initiative by previewing several works-in-progress imaging systems.

Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice.

Cloud Storage

Business and technology analyst Ovum has published three “Trends to Watch" reports on cloud computing and reveals that 2013 will see cloud computing continue to grow rapidly.

Mach 7 Technologies unveiled the latest version of its enterprise clinical imaging platform, Keystone Suite, at the 98th annual meeting of the Radiological Society of North America (RSNA) in November 2012.

PenRad’s mammography information system (MIS) has been named the Category Leader in the “2012 Best in KLAS Awards: Software and Services” report for MIS technology for the fifth consecutive year by KLAS. KLAS rankings are based on product quality, ease-of-use and price, as well as customer support according to evaluations given by system users. Since KLAS began analyzing the MIS market in 2008, PenRad MIS has won the Category Leader each year consecutively.

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced today that Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.[1]

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now